论文部分内容阅读
目的研究DHAX±R方案(地塞米松、大剂量阿糖胞苷、奥沙利铂±利妥昔单抗)治疗非霍奇金淋巴瘤(NHL)的临床疗效和不良反应。方法接受DHAX±R方案化疗的NHL患者20例,其中初发患者7例,复发难治性13例,中位年龄67岁。观察NHL患者接受治疗后的临床疗效以及不良反应的发生情况。结果初发和复发难治性患者治疗后的总有效率分别为85.7%和69.2%。20例患者随访3-33个月,4例初发患者和7例复发难治性患者死亡。复发难治性患者的中位无进展生存期为9个月,中位总生存期为16个月。主要不良反应为骨髓抑制,无3-4级非血液学毒性,无肾毒性。结论 DHAX±R方案治疗NHL的临床疗效良好,不良反应可耐受,适合于老年患者。
Objective To investigate the clinical efficacy and adverse effects of DHAX ± R regimen (dexamethasone, high dose cytarabine, oxaliplatin ± rituximab) in the treatment of non-Hodgkin’s lymphoma (NHL). Methods Twenty NHL patients undergoing DHAX ± R chemotherapy were recruited. Among them, 7 were initially diagnosed and 13 were refractory to recurrence. The median age was 67 years. To observe the clinical efficacy of NHL patients after treatment and the incidence of adverse reactions. Results The total effective rates after initial treatment and recurrence refractory were 85.7% and 69.2% respectively. Twenty patients were followed up for 3-33 months, 4 patients were newly diagnosed and 7 patients were refractory to recurrence. Median progression-free survival in relapsed and refractory patients was 9 months, with a median overall survival of 16 months. The main adverse reactions were myelosuppression, no grade 3-4 non-hematologic toxicity, no nephrotoxicity. Conclusion The clinical efficacy of DHAX ± R regimen in the treatment of NHL is good and the adverse reactions are tolerable. It is suitable for elderly patients.